Portugal’s PFx Biotech Secures €5M to Produce Bioidentical Human Milk Proteins Through Precision Fermentation

Portuguese startup PFx Biotech has secured €5 million in funding to produce bioidentical human milk proteins through precision fermentation. The seed funding round was led by Buenavista Equity Partners, with support from EIT Food and Beta Capital, and a grant from the European Innovation Council and SMEs Executive Agency. The company aims to provide sustainable, non-GMO, and allergen-free nutritional solutions for various life stages, including infants, athletes, and the elderly.

The new capital will be used to fund lab facilities, expand the team, and scale up production of PFx Biotech’s lactoferrin. PFx Biotech is open to strategic partnerships in research and development, scale-up, and commercialization. The company is part of a global trend of companies working to produce alternatives to human milk, with a focus on providing innovative and sustainable nutrition solutions.